Phase 1 restored the signal. Phase 2 puts the signal to work — locally, at the muscle fiber, where new tissue is actually built. The pituitary is now pulsing GH on a near-physiological rhythm thanks to four weeks of CJC + Ipamorelin. IGF-1 is climbing back into the upper-physiological range. The substrate (signaling environment) is primed. What the corpus describes next is the deliberate addition of two compounds that operate downstream of the GH axis: one that drives a brief, intense, site-specific anabolic pulse at the muscle level (IGF-1 LR3), and one that holds GH/IGF-1 elevated 24/7 in the background between LR3 injections (MK-677). This is the layer where hypertrophy and hyperplasia start showing up on the scale, in the mirror, and on DEXA.
What's actually happening at the cellular level
The Phase 1 axis (CJC + Ipamorelin) gives you GH pulsatility. GH then signals the liver to produce IGF-1, which gets packaged with binding proteins and shipped systemically. That's the indirect path — slow, distributed, and capped by hepatic IGF-1 production capacity. The practitioner corpus describes IGF-1 LR3 as the way to bypass that bottleneck. LR3 is a synthetic IGF-1 analog with an N-terminal extension (the "LR3" tag) that prevents IGF binding proteins from sequestering it. The result: it's roughly 10× more potent than native IGF-1, with a half-life around 20–30 minutes. That brief activity window is a feature, not a bug — it enables precise, site-specific delivery when injected directly into the target muscle. The compound binds local IGF-1 receptors, activates PI3K/Akt, drives protein synthesis, increases nitrogen retention, and — critically for Phase 2 — stimulates satellite cell fusion.
This is where the hyperplasia mechanism actually lives. Skeletal muscle has two pathways for mass gain: hypertrophy (existing fibers get bigger) and hyperplasia (new fibers are created). Most exogenous anabolics drive hypertrophy. The practitioner corpus is consistent that IGF-1 LR3 is one of the few compounds that meaningfully recruits hyperplasia by mobilizing dormant satellite cells, fusing them to existing fibers, and — in some descriptions — supporting the creation of net-new muscle fibers. This is why corpus-described LR3 protocols emphasize bilateral injection into the same muscle group during the rebuild phase. You're not chasing a systemic effect. You're chasing local fiber-count change in the tissue you actually want to grow.
MK-677 (ibutamoren) operates on the other axis. It's an orally bioavailable ghrelin mimetic — it binds the ghrelin receptor on the pituitary and triggers GH release, but unlike Ipamorelin's discrete pulses, it elevates baseline GH secretion 24/7 for the duration of the half-life. The clinical data the corpus references shows large increases in serum IGF-1, increased osteocalcin within two months, and reported gains of 5–10 pounds of fat-free mass within the first few weeks at therapeutic doses. Mechanistically MK-677 is not adding new GH events — it's increasing the amplitude of existing secretion. The corpus is explicit on the dose ceiling: clinical data shows MK-677 begins exhibiting diminishing returns above 25 mg per day, and this remains consistent across the majority of studies.
The two compounds compose: LR3 gives you the local, fiber-level anabolic spike on training days; MK-677 keeps the systemic IGF-1/GH milieu elevated continuously so recovery and protein synthesis run hot between LR3 doses.
Phase 2 protocol stack (Week 5–10)
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| IGF-1 LR3 | [practitioner corpus thin on specific mcg dosing in retrieved substrate — track and report] | SubQ or intramuscular into target muscle | Pre- or post-training on lift days; bilateral injection into worked muscle group | 🟢 Expert | Half-life 20–30 min. Inject within the post-training anabolic window. Rotate target muscle weekly. |
| MK-677 | 25 mg | Oral | Nightly, with or after final meal | 🟢 Expert | Diminishing returns above 25 mg/day per clinical data. Nightly dosing leverages sleep-window GH amplification. |
| CJC-1295 (no DAC) | continue Phase 1 dose | SubQ | continue Phase 1 schedule | 🟢 Expert | Do not drop. LR3 and MK-677 are layered on top of Phase 1, not replacing it. |
| Ipamorelin | continue Phase 1 dose | SubQ | continue Phase 1 schedule | 🟢 Expert | Maintains pulsatility underneath MK-677's tonic elevation. |
Critical layering note from the corpus: Running multiple GH-axis compounds simultaneously requires disciplined timing and site management. Do not combine LR3 injection timing with morning fasted CJC/Ipa — separate them by at least 4 hours to keep the signals distinguishable and the injection burden manageable.
Critical insulin note from the corpus: Combined insulin antagonism from multiple GH pathways can overwhelm pancreatic compensation. The corpus is explicit that MK-677 commonly elevates fasting glucose and reduces insulin sensitivity, and that chronic IGF-1 elevation above 350 ng/mL is associated with increased cancer risk in epidemiological studies. Phase 2 is the phase where bloodwork stops being optional. Pull fasting glucose, fasting insulin, HbA1c, and IGF-1 at Week 6 and Week 10.
What you should feel
- Week 5: Appetite increase from MK-677 — sometimes dramatic. This is the ghrelin-mimetic effect; the body is being tricked into hunger. Use it to drive caloric intake into the surplus that the rebuild requires.
- Week 5–6: Deeper sleep, particularly slow-wave sleep, from elevated nightly GH. Vivid dreams are common and corpus-described.
- Week 6: First measurable scale change — corpus references 5–10 lb fat-free mass within the first few weeks of MK-677 in the clinical literature, though water retention contributes to early gains.
- Week 7–8: Localized fullness and pump quality in the target muscle group worked with LR3 — practitioners describe this as the most reliable subjective signal that LR3 is being delivered into the right tissue.
- Week 9–10: Strength PRs begin showing up — not from LR3 directly (LR3 is a tissue-building signal, not a neural one) but because the rebuilt cross-sectional area is now expressing on the bar.
What's NOT happening yet
- Cancer risk from a single 6-week cycle. The corpus is consistent that the cancer-risk signal in the epidemiological literature is associated with chronic IGF-1 elevation above 350 ng/mL, not transient peaks. The risk discipline is bloodwork, not avoidance.
- Pure lean tissue gain. Some of the Week 5–6 scale change is water and glycogen — both MK-677 and elevated GH drive intracellular hydration. The lean mass underneath will become visible after Week 8 as the water effect normalizes.
- A free pass on insulin resistance. This is the most under-appreciated risk in the corpus. If your Week 6 fasting glucose climbs above ~95 or fasting insulin above ~8 μIU/mL, you stop adding GH pressure and reassess before Phase 2 continues. The corpus is explicit: GH secretagogues worsen insulin resistance in anyone already trending that direction.
- Permanent anabolism. LR3 and MK-677 are signals, not substrates. Without the caloric surplus, the training stimulus, and the protein intake to match, the signaling does nothing. The corpus repeatedly frames these compounds as amplifiers of training, not replacements for it.
- A reason to push LR3 dose higher. The corpus references that the brief 20–30 minute half-life is the safety mechanism — chasing a longer or larger LR3 effect by upping the dose drives toward systemic hypoglycemia and supraphysiological IGF-1 exposure. Site-specific, time-bounded delivery is the strategy.
Research describes this. Track IGF-1, fasting insulin, and fasting glucose at Week 6 and Week 10. Adjust.